NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial [Yahoo! Finance]
NanoViricides, Inc. (NNVC)
NASDAQ:AMEX Investor Relations:
nanoviricides.com/investorinfo.html
Company Research
Source: Yahoo! Finance
NanoViricides (NYSE-A:NNVC) said on Wednesday it has completed manufacturing of its NV-387 oral drug product, clearing a key step toward dosing patients in an upcoming clinical trial for mpox. The clinical-stage antiviral drug developer said the drug product, formulated as “NV-387 Oral Gummies,” is ready for use once clinical trial sites are prepared to begin patient dosing. NV-387, the company's lead clinical-stage candidate, has received approval from the Democratic Republic of Congo's regulatory agency ACOREP to enter a Phase II clinical trial for the treatment of mpox. The oral antiviral previously completed a Phase I clinical trial in healthy volunteers with no reported adverse events or participant dropouts, the company said, indicating strong safety and tolerability. NanoViricides said NV-387 is designed as a broad-spectrum antiviral therapy targeting multiple respiratory and viral infections, including respiratory syncytial virus (RSV), influenza, coronaviruses includ
Show less
Read more
Impact Snapshot
Event Time:
NNVC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NNVC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NNVC alerts
High impacting NanoViricides, Inc. news events
Weekly update
A roundup of the hottest topics
NNVC
News
- NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMI [Yahoo! Finance]Yahoo! Finance
- NanoViricides: Fiscal Q2 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- NanoViricides seeks FDA orphan status for MPox drug [Yahoo! Finance]Yahoo! Finance
- NanoViricides (NYSE:NNVC) is now covered by analysts at Alliance Global Partners. They set a "buy" rating on the stock.MarketBeat
NNVC
Sec Filings
- 2/25/26 - Form D
- 2/17/26 - Form 10-Q
- 12/30/25 - Form 424B3
- NNVC's page on the SEC website